Eichenbaum Kenneth D.

Director Eichenbaum buys 2,000 INFU shares at $5.18; stock -45.1% from 52-week high, prior buy gained +41.1% over 90 days, cluster of 3 other insider buys in past 14 days.

Director Kenneth D. Eichenbaum purchased 2,000 shares at $5.18, increasing his holdings by 50.0% to 6,000 shares total. The transaction occurs with the stock trading -45.1% from its 52-week high of $9.51, and notably, Eichenbaum's single prior buy at this ticker on 2024-09-23 delivered a 90-day return of +41.1%, suggesting his previous buy was well-timed. Additionally, 3 other insiders have purchased within the past 14 days, forming a cluster buy pattern that extends beyond this director's individual decision. The fundamental backdrop shows net income at $-267.0K (latest quarter) against $34.7M in revenue, with a P/E of 34.80, indicating the stock is expensive relative to near-term profitability despite modest 7.2% annual revenue growth.

Director Kenneth D. Eichenbaum bought 4,000 INFU shares at $5.89 on 2024-09-23, opening a new position worth $23.6K

Kenneth D. Eichenbaum, a director, purchased 4,000 shares at $5.89 on 2024-09-23, establishing an initial position in InfuSystem Holdings. The transaction occurred near the lower end of the 52-week range of $5.80–$10.89, approximately 45.3% below the high. InfuSystem reported recent quarterly revenue of $33.7M with net income of $717.0K and annual revenue growth of 14.4%, but the company trades at a P/E of 298.00, indicating either minimal recent profitability relative to price or elevated valuation expectations. The stock has declined 7.4% over the past 30 days and 13.0% over 90 days, suggesting challenging near-term momentum at the time of this insider purchase.